The outcomes from a randomised, double-blind study has demonstrated significant reductions in T2DM, hypertension and obstructive sleep apnoea (OSA) after four months on the Allurion Program. These results improved with the addition of oral GLP-1 agonist semaglutide.
In the study, 115 patients were randomised to either the Allurion Program with or without oral semaglutide and followed for four months. In patients randomised to the Allurion Program alone, weight loss was 13.7% at four months and resolution of type 2 diabetes, hypertension and obstructive sleep apnoea was observed in 55.5%, 58.8%, and 57.8%, respectively. Weight loss improved to 17.6% in the group treated with the Allurion Program and oral semaglutide and co-morbidity resolution improved to 64.7%, 64.3%, and 72%, respectively.
“We have been extremely pleased with the results we are seeing in medically complex patients with the Allurion Program, especially the speed with which co-morbidities resolve,” said Dr Mohit Bhandari, President of IRCAD India and senior author on the study. “We have seen that oral GLP-1 agonists alone are often insufficient to generate such significant results but using them as a tool to augment the results of the Allurion Program could be a promising treatment approach in the future.”
Allurion recently published findings indicating that providers are interested in combining the Allurion Program with anti-obesity medications and that the rise of GLP-1 agonists has increased patient enquiries and boosted awareness of weight loss treatments like the Allurion Program.
“We believe the results of this study provide further validation of the rapid impact the Allurion Program can have in patients with obesity and other co-morbidities,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “By combining the Allurion Program with anti-obesity medications, we may be able to improve outcomes even further and reach an even broader segment of the population."
The findings were featured in the paper, 'Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study', published in Obesity Surgery. Please click here to access this paper (log-in maybe required)
Comments